Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 107-116

  Comin Anduix, Begoña ^a   Gualberto, Antonio ^c   Glaspy, John A ^a,b   Seja, Elisabeth ^a   Ontiveros, Maribel ^a   Reardon, Deborah L ^c   Renteria, Roberto ^d   Englahner, Brigitte ^c   Economou, James S ^a,b   Gomez Navarro, Jesus ^c   Ribas, Antoni ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d BECKMAN COULTER INC   (United States)

^e UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CP 675206; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; MONOCLONAL ANTIBODY; TACILIMUMAB; TETRAMER; UNCLASSIFIED DRUG;

ACCURACY; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; EXPOSURE; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REFERENCE VALUE; T LYMPHOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOTHERAPY; INTERFERON TYPE II; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES;

EID: 31544440474     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0136     Document Type: Article

References (34)

1. Czerkinsky C, Andersson G, Ekre HP, et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of γ-interferon- secreting cells. J Immunol Methods 1988;110:29-36.
2. Tanguay S, Killion JJ. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res 1994;13:259-63.
3. + T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-42.
4. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 1997;210:167-74.
5. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
6. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of by-stander activation during viral infection. Immunity 1998;8:177-87.
7. Labalette-Houache M, Torpier G, Capron A, et al. Improved permeabilization procedure for flow cytometric detection of internal antigens. Analysis of interleukin-2 production. J Immunol Methods 1991;138:143-53.
8. Chikanza IC, Corrigal V, Kingsley G, et al. Enumeration of interleukin-1 α and β producing cells by flow cytometry. J Immunol Methods 1992;154:173-8.
9. Clay TM, Hobeika AC, Mosca PJ, et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001;7:1127-35.
10. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97-138.
11. Whiteside TL. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin Diagn Lab Immunol 2000;7:327-32.
12. Hobeika AC, Morse MA, Osada T, et al. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 2005;28:63-72.
13. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
14. Harris EK, Brown SS. Temporal changes in the concentrations of serum constituents in healthy men. Distributions of within-person variances and their relevance to the interpretation of differences between successive measurements. Ann Clin Biochem 1979;16:169-76.
15. Harris EK, Yasaka T. On the calculation of a "reference change" for comparing two consecutive measurements. Clin Chem 1983;29:25-30.
16. Harris EK. Reference values for change: an addendum. Clin Chem 1983;29:997.
17. Queralto JM, Boyd JC, Harris EK. On the calculation of reference change values, with examples from a long-term study. Clin Chem 1993;39:1398-403.
18. Fraser CG. Biological variation: from principles to practice. Washington (DC): AACC Press: 2001.
19. Trape J, Botargues JM, Porta F, et al. Reference change value for α-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003;49:1209-11.
20. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses after CTLA4 blockade with the monoclonal antibody CP-675.206. Journal of Clinical Oncology 2005;23: 10.1200/JCO.205.01. 109. [epub ahead of print].
21. Maecker HT, Moon J, Bhatia S, et al. Impact of cryopreservation on tetramer, cytokine flow, and ELISPOT. BMC Immunol 2005;6:17.
22. Britten CM, Meyer RG, Kreer T, et al. The use of HLA-A*0201- transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-γ ELISPOT assays. J Immunol Methods 2002;259:95-110.
23. Westgard JO. Westgard QC: tools, technology and training for healthcare laboratories. Available from: http://www.westgard.com 2005.
24. Butterfield LH, Meng WS, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein. J Immunol 2001;166:5300-8.
25. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003;9:998-1008.
26. Ribas A, Glaspy JA, Lee Y, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004;27:354-67.
27. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
28. Panelli MC, Riker A, Kammula U, et al. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 2000;164:495-504.
29. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997;3:221-6.
30. Arlen P, Tsang KY, Marshall JL, et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000;49:517-29.
31. Ribas A, Butterfield LH, Glaspy JA, et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-32.
32. + T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-γ ELISPOT assays for patient immune monitoring. J Immunother 2004;27:298-308.
33. Hoffmann TK, Donnenberg VS, Friebe-Hoffmann U, et al. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry 2000;41:321-8.
34. Asai T, Storkus WJ, Whiteside TL. Evaluation of the modified ELISPOT assay for γ interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol 2000;7:145-54.